← Back to Clinical Trials
Recruiting NCT06682481

NCT06682481 Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06682481
Status Recruiting
Phase
Sponsor Philippe Klee, MD-PhD
Condition Obesity, Childhood
Study Type OBSERVATIONAL
Enrollment 50 participants
Start Date 2024-11-22
Primary Completion 2028-12-31

Eligibility & Interventions

Sex All sexes
Min Age 12 Years
Max Age 16 Years
Study Type OBSERVATIONAL
Interventions
Measurement of biomarker

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 50 participants in total. It began in 2024-11-22 with a primary completion date of 2028-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The investigators will measure blood levels of 1,5-anhydroglucitol in obese children with or without type 2 diabetes and correlate them with parameters related to functional beta-cell mass and glucose metabolism. The values will be compared to those obtained in healthy volunteers. The aim of the study is to test the validity of 1,5-anhydroglucitol as a novel biomarker of beta-cell mass and function in children with obesity with or without type 2 diabetes.

Eligibility Criteria

Inclusion Criteria: * Children aged 12 to 16 years * Obesity. Defined as a body-mass index above the 97th percentile. * Ability to give informed consent as documented by signature Exclusion Criteria: * Patients with diabetes mellitus and positive autoantibodies against islets, insulin, islet antigen 2, glutamic acid decarboxylase or Zinc transporter 8. * Patients with known liver disease (other than NAFLD) * Patients treated with an oral antidiabetic drug, glucagon-like peptide-1 analogues or insulin at the time of or less than 2 weeks prior to inclusion. * Patients treated with a drug known to affect liver function

Contact & Investigator

Central Contact

Philippe Klee

✉ philippe.klee@unige.ch

📞 +41 79 55 33 476

Frequently Asked Questions

Who can join the NCT06682481 clinical trial?

This trial is open to participants of all sexes, aged 12 Years or older, up to 16 Years, studying Obesity, Childhood. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06682481 currently recruiting?

Yes, NCT06682481 is actively recruiting participants. Contact the research team at philippe.klee@unige.ch for enrollment information.

Where is the NCT06682481 trial being conducted?

This trial is being conducted at Geneva, Switzerland.

Who is sponsoring the NCT06682481 clinical trial?

NCT06682481 is sponsored by Philippe Klee, MD-PhD. The trial plans to enroll 50 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology